You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthosuximide
Accession NumberDB00593  (APRD00318)
TypeSmall Molecule
GroupsApproved
DescriptionAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]
Structure
Thumb
Synonyms
(+-)-2-Ethyl-2-methylsuccinimide
(±)-2-ethyl-2-methylsuccinimide
2-ethyl-2-methylsuccinimide
2-Methyl-2-ethylsuccinimide
3-ethyl-3-methyl-2,5-pyrrolidinedione
3-Ethyl-3-methylsuccinimide
3-Methyl-3-ethylpyrrolidine-2,5-dione
3-Methyl-3-ethylsuccinimide
Aethosuximide
alpha-Ethyl-alpha-methylsuccinimide
alpha-Methyl-alpha-ethylsuccinimide
Atysmal
Ethosuximid
Ethosuximide
Ethosuximidum
Etosuximida
gamma-Ethyl-gamma-methyl-succinimide
gamma-Methyl-gamma-ethyl-succinimide
Thilopemal
γ-ethyl-γ-methyl-succinimide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EthosuximideCapsule250 mg/1OralGreenstone LLC2000-09-22Not applicableUs
ZarontinCapsule250 mg/1OralParke Davis Div Of Pfizer Inc2000-09-22Not applicableUs
Zarontin Cap 250mgCapsule250 mgOralErfa Canada 2012 Inc1960-12-31Not applicableCanada
Zarontin Syr 250mg/5mlSyrup250 mgOralErfa Canada 2012 Inc1964-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EthosuximideCapsule250 mg/1OralAvera Mc Kennan Hospital2015-10-30Not applicableUs
EthosuximideSolution250 mg/5mLOralPharmaceutical Associates, Inc.2000-11-22Not applicableUs
EthosuximideSolution250 mg/5mLOralGreenstone LLC2002-02-27Not applicableUs
EthosuximideCapsule250 mg/1OralVersa Pharm Incorporated2008-09-01Not applicableUs
EthosuximideSolution250 mg/5mLOralMikart, Inc.2003-12-22Not applicableUs
EthosuximideCapsule, liquid filled250 mg/1OralBionpharma Inc.2016-10-21Not applicableUs
EthosuximideCapsule250 1/1OralZydus Pharmaceuticals (USA) Inc.2012-10-10Not applicableUs
EthosuximideSolution250 mg/5mLOralTeva Pharmaceuticals Usa, Inc.1994-07-01Not applicableUs
EthosuximideCapsule250 mg/1OralPliva Inc.2002-11-01Not applicableUs
EthosuximideCapsule, liquid filled250 mg/1OralBanner Life Sciences Llc.2015-06-01Not applicableUs
EthosuximideCapsule250 mg/1OralHeritage Pharmaceuticals Inc.2012-10-10Not applicableUs
EthosuximideSolution250 mg/5mLOralVersa Pharm Incorporated2004-01-01Not applicableUs
ZarontinSolution250 mg/5mLOralParke Davis Div Of Pfizer Inc2002-02-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EmesideChemidex
EthymalApotex Europe
EtoxinApsen
PetimidOsel
PetinimidGerot
PetnidanDesitin
SuxilepJenapharm
SuxinutinMcNeil
ZarondanPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5SEH9X1D1D
CAS number77-67-8
WeightAverage: 141.1677
Monoisotopic: 141.078978601
Chemical FormulaC7H11NO2
InChI KeyHAPOVYFOVVWLRS-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
IUPAC Name
3-ethyl-3-methylpyrrolidine-2,5-dione
SMILES
CCC1(C)CC(=O)NC1=O
Pharmacology
IndicationFor the treatment of petit mal epilepsy.
Structured Indications
PharmacodynamicsUsed in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
Mechanism of actionBinds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent T-type calcium channel subunit alpha-1GProteinyes
inhibitor
HumanO43497 details
Related Articles
AbsorptionBioavailability following oral administration is 93%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic, via CYP3A4 and CYP2E1.

Route of eliminationNot Available
Half life53 hours
ClearanceNot Available
ToxicityAcute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethosuximide.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ethosuximide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethosuximide.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Ethosuximide.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethosuximide.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethosuximide.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethosuximide.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethosuximide.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ethosuximide.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethosuximide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethosuximide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethosuximide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethosuximide.Experimental
AmphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Amphetamine.Approved, Illicit
AprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethosuximide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ethosuximide.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethosuximide.Approved
AtazanavirThe metabolism of Ethosuximide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ethosuximide can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ethosuximide.Vet Approved
AzelastineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethosuximide.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethosuximide.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethosuximide.Approved
BenzphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ethosuximide.Approved
BexaroteneThe serum concentration of Ethosuximide can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Ethosuximide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ethosuximide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ethosuximide.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethosuximide.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ethosuximide.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethosuximide.Approved, Investigational
BuprenorphineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ethosuximide.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethosuximide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ethosuximide.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethosuximide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethosuximide.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Ethosuximide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethosuximide.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.Approved
CeritinibThe serum concentration of Ethosuximide can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethosuximide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethosuximide.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethosuximide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethosuximide.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethosuximide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Chlorphenamine.Approved
ChlorphentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethosuximide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethosuximide.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethosuximide.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.Approved
ClarithromycinThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ethosuximide can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethosuximide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ethosuximide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.Approved, Illicit
ClotrimazoleThe metabolism of Ethosuximide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethosuximide.Approved
CobicistatThe serum concentration of Ethosuximide can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethosuximide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.Approved, Illicit
ConivaptanThe serum concentration of Ethosuximide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ethosuximide can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.Approved
CyclosporineThe metabolism of Ethosuximide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethosuximide.Approved
Cyproterone acetateThe serum concentration of Ethosuximide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethosuximide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Ethosuximide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ethosuximide can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ethosuximide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ethosuximide.Vet Approved
DexamethasoneThe serum concentration of Ethosuximide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethosuximide.Approved, Vet Approved
DextroamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Dextroamphetamine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethosuximide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethosuximide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethosuximide.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethosuximide.Approved, Illicit, Vet Approved
DiethylpropionThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.Approved, Illicit
DihydroergotamineThe metabolism of Ethosuximide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethosuximide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethosuximide.Experimental, Illicit
DiltiazemThe metabolism of Ethosuximide can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethosuximide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethosuximide.Approved, Illicit
DisulfiramThe metabolism of Ethosuximide can be decreased when combined with Disulfiram.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ethosuximide.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxepin.Approved
DoxycyclineThe metabolism of Ethosuximide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethosuximide.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Illicit
DronedaroneThe metabolism of Ethosuximide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ethosuximide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethosuximide.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ethosuximide.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethosuximide.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethosuximide.Approved, Investigational
EnzalutamideThe serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ethosuximide can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ethosuximide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethosuximide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethosuximide.Approved
EthanolEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide.Approved, Illicit, Withdrawn
EthotoinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethosuximide.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethosuximide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethosuximide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ethosuximide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ethosuximide.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ethosuximide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethosuximide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethosuximide.Illicit, Vet Approved
EtravirineThe serum concentration of Ethosuximide can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethosuximide.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethosuximide.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.Approved
FluconazoleThe metabolism of Ethosuximide can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethosuximide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethosuximide.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethosuximide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethosuximide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethosuximide.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ethosuximide.Approved
FluvoxamineThe metabolism of Ethosuximide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ethosuximide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ethosuximide.Approved, Illicit
Fusidic AcidThe serum concentration of Ethosuximide can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethosuximide.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethosuximide is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethosuximide.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethosuximide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethosuximide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethosuximide.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethosuximide.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethosuximide.Approved
HydrocodoneEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.Approved, Illicit
Hydroxyamphetamine hydrobromideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
IdelalisibThe serum concentration of Ethosuximide can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iloperidone.Approved
ImatinibThe metabolism of Ethosuximide can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethosuximide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Ethosuximide can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Ethosuximide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethosuximide.Approved, Vet Approved
IsoniazidThe metabolism of Ethosuximide can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Ethosuximide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ethosuximide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ethosuximide can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethosuximide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethosuximide.Approved
KetoconazoleThe metabolism of Ethosuximide can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethosuximide.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethosuximide.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethosuximide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethosuximide.Approved, Vet Approved
LisdexamfetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Lisdexamfetamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethosuximide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ethosuximide.Illicit
LopinavirThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethosuximide.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.Approved
LovastatinThe metabolism of Ethosuximide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Ethosuximide.Investigational
LuliconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ethosuximide can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ethosuximide.Vet Approved
MefloquineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethosuximide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ethosuximide.Approved
MephedroneThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephedrone.Investigational
MephentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethosuximide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethosuximide.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethosuximide.Approved, Illicit
MethamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethosuximide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ethosuximide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethosuximide.Approved
MethotrimeprazineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethosuximide.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethosuximide.Approved
MetyrosineEthosuximide may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.Approved, Illicit
MifepristoneThe serum concentration of Ethosuximide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Investigational
MirtazapineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ethosuximide can be decreased when it is combined with Mitotane.Approved
MMDAThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with MMDA.Experimental, Illicit
ModafinilThe serum concentration of Ethosuximide can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ethosuximide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved, Investigational
NafcillinThe serum concentration of Ethosuximide can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethosuximide.Approved
NefazodoneThe metabolism of Ethosuximide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ethosuximide can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ethosuximide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ethosuximide can be increased when combined with Nevirapine.Approved
NicotineThe metabolism of Ethosuximide can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethosuximide.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethosuximide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ethosuximide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethosuximide.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethosuximide.Approved, Investigational
OlaparibThe metabolism of Ethosuximide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethosuximide.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ethosuximide.Approved, Illicit
OrlistatThe serum concentration of Ethosuximide can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethosuximide.Investigational
OsimertinibThe serum concentration of Ethosuximide can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethosuximide.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethosuximide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethosuximide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethosuximide.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethosuximide.Approved
ParaldehydeEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.Approved, Vet Approved
PentobarbitalThe metabolism of Ethosuximide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethosuximide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethosuximide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethosuximide.Approved
PhenobarbitalThe metabolism of Ethosuximide can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ethosuximide.Approved
PhentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phentermine.Approved, Illicit
PhenytoinEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethosuximide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethosuximide.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ethosuximide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleEthosuximide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethosuximide.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethosuximide.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethosuximide.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethosuximide.Approved
PrimidoneThe metabolism of Ethosuximide can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethosuximide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethosuximide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ethosuximide.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ethosuximide.Investigational
PseudoephedrineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethosuximide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Ethosuximide can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethosuximide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.Approved
RifabutinThe metabolism of Ethosuximide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ethosuximide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethosuximide can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ritanserin.Investigational
RitobegronThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Ritobegron.Investigational
RitonavirThe metabolism of Ethosuximide can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ethosuximide.Vet Approved
RopiniroleEthosuximide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethosuximide.Approved
RotigotineEthosuximide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethosuximide.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sage 547.Investigational
SaquinavirThe metabolism of Ethosuximide can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethosuximide.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ethosuximide.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethosuximide.Approved, Vet Approved
SildenafilThe metabolism of Ethosuximide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ethosuximide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ethosuximide can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
St. John's WortThe serum concentration of Ethosuximide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ethosuximide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.Approved, Investigational
SulfisoxazoleThe metabolism of Ethosuximide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethosuximide.Approved
SuvorexantEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Ethosuximide can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Ethosuximide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethosuximide.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ethosuximide.Investigational
ThalidomideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethosuximide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethosuximide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethosuximide.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiapride.Investigational
TiclopidineThe metabolism of Ethosuximide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ethosuximide.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethosuximide.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethosuximide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethosuximide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethosuximide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethosuximide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethosuximide.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethosuximide.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethosuximide.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethosuximide.Approved
Uc1010The risk or severity of adverse effects can be increased when Ethosuximide is combined with Uc1010.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ethosuximide.Approved, Investigational
VenlafaxineThe metabolism of Ethosuximide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ethosuximide can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Ethosuximide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ethosuximide.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ethosuximide.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethosuximide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ethosuximide can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ethosuximide.Vet Approved
ZolpidemEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethosuximide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ethosuximide.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethosuximide.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
References
Synthesis Reference

Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.

General References
  1. Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8. [PubMed:16302888 ]
  2. Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8. [PubMed:2710401 ]
  3. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161 ]
  4. Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6. [PubMed:2169941 ]
  5. Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8. [PubMed:1336826 ]
External Links
ATC CodesN03AD51N03AD01
AHFS Codes
  • 28:12.20
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (73.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9983
Caco-2 permeable+0.5262
P-glycoprotein substrateNon-substrate0.5832
P-glycoprotein inhibitor INon-inhibitor0.7859
P-glycoprotein inhibitor IINon-inhibitor0.9923
Renal organic cation transporterNon-inhibitor0.8867
CYP450 2C9 substrateNon-substrate0.8492
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5108
CYP450 1A2 substrateNon-inhibitor0.9242
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9276
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.93
Ames testNon AMES toxic0.858
CarcinogenicityNon-carcinogens0.8526
BiodegradationNot ready biodegradable0.9299
Rat acute toxicity1.9213 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.9795
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Convenant pharma inc
  • Parke davis div warner lambert co
  • Mikart inc
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Parke davis pharmaceutical research div warner lambert co
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 1/1
CapsuleOral250 mg/1
Capsule, liquid filledOral250 mg/1
SolutionOral250 mg/5mL
CapsuleOral250 mg
SyrupOral250 mg
Prices
Unit descriptionCostUnit
Ethosuximide 250 mg/5ml Solution 474ml Bottle84.2USD bottle
Ethosuximide 250 mg capsule1.26USD capsule
Zarontin 250 mg capsule1.16USD capsule
Zarontin 250 mg/5ml Solution0.34USD ml
Zarontin 50 mg/ml Syrup0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point64.5 °CPhysProp
water solubility39.2 g/LNot Available
logP0.38ATKINSON,HC & BERG,EJ (1988)
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP0.1ALOGPS
logP0.55ChemAxon
logS-0.15ALOGPS
pKa (Strongest Acidic)10.73ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.17 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity35.96 m3·mol-1ChemAxon
Polarizability14.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.34 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-08mi-9300000000-3d87944377ee1f85803dView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dicarboximides. These are carboxylic acid amides in which the two acyl groups linked to the central nitrogen atoms are carboacyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentDicarboximides
Alternative Parents
Substituents
  • Dicarboximide
  • 2-pyrrolidone
  • Pyrrolidone
  • Pyrrolidine
  • Carboxylic acid imide, n-unsubstituted
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441 ]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061 ]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23